The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The future of next-generation sequencing assays in myeloma treatment
Shankara Anand, MS, Broad Institute of MIT & Harvard, Cambridge, MA, highlights the need for advances to be made in the use of next-generation sequencing (NGS) assays in a clinical setting, and current challenges with the financial costs of these assays. Mr Anand then discusses the benefit that these sequencing panels could bring to the future of risk stratification models and patient care in myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
